Copyright
©The Author(s) 2023.
World J Clin Cases. Aug 16, 2023; 11(23): 5538-5546
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5538
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5538
Table 2 Literature review of membranous nephropathy with amyloidosis
Ref. | No. | Patient | Country | Age | Sex | Proteinuria (g/d) | Scr (μmol/L) | ALB (g/L) |
Kuroda et al[9], 2012 | 6 | Japan | NA | NA | NA | NA | NA | |
Lu et al[10], 2017 | 1 | Patient 1 | China | 64 | M | 10.06-10.52 | 77.35 | 26.7 |
Li et al[11], 2020 | 4 | Patient 4 | China | 74 | F | 11.26 | 118 | 26.5 |
Patient 5 | China | 61 | F | 2.44 | 76 | 22.3 | ||
Patient 6 | China | 79 | M | 7.92 | 541.8 | 24.7 | ||
Patient 7 | China | 61 | F | 3.89 | 70.2 | 31.4 | ||
Morel et al[12], 2022 | 1 | France | 56 | M | UPCR 522 mg/mmol (after 6 years) | eGFR 78.9 mL/min/1.73 m2 (after 6 years) | 23 (after 6 years) | |
Wang et al[13], 2022 | 1 | China | 39 | M | 8.01 | 95.3 | 13.1 | |
The present case | 1 | China | 48 | M | 17.84 | 97.3 | 18.3 |
- Citation: Zhang J, Wang X, Zou GM, Li JY, Li WG. Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report. World J Clin Cases 2023; 11(23): 5538-5546
- URL: https://www.wjgnet.com/2307-8960/full/v11/i23/5538.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i23.5538